linjc16/ctgov huggingface dataset:
Testing the Efficacy of a Post-discharge Call Program on the Rate of Readmission

Study Overview
=================
Brief Summary
-----------------
NYU Langone Health patients receive a call from a clinical care coordinator after they are discharged from the hospital (within 1-3 days). The current study is testing the efficacy of this program.

Official Title
-----------------
Testing the Efficacy of a Post-discharge Call Program on the Rate of Readmission

Conditions
-----------------
Care Transitions

Intervention / Treatment
-----------------
* Other: Post-discharge call


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients discharged from NYU Langone Health who are eligible to receive a call from a clinical care coordinator after they were discharged from the hospital. Exclusion Criteria: N/A
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Post-discharge call<br>Patients in this arm will receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health. | Other: Post-discharge call<br>* Patients will receive a call 1-3 days after they were discharged from the hospital to make sure their healthcare needs are being met.<br>|
| No Intervention: No post-discharge call<br>Patients in this arm will not receive a call from a clinical care coordinator after they have been discharged from NYU Langone Health. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of readmission | Number of patients admitted to a hospital within after being discharged from an earlier hospital stay. | 6 months |
QOL, ADL and Pain Before and After Intervention With N3 From Krill With D3.

Study Overview
=================
Brief Summary
-----------------
The aim of this project is investigation of patients' with chronic pain self-rated quality of life, ADL function and level of pain before and after 3 months of intervention with N-3 fatty acids from krill in combination with vitamin D3. Furthermore, the compliance of the patients and the effect of the intervention on the patients' vitamin D status and cardiovascular risk factors are studied.

Official Title
-----------------
Survey of Chronic Pain Patients' Self-rated Quality of Life, ADL Function and Pain Before and After Intervention With Omega 3 Fatty Acids From Krill With Vitamin D3

Conditions
-----------------
Quality of Life, Pain

Intervention / Treatment
-----------------
* Dietary Supplement: Omega Krill with D3


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 year + can read and understand danish Exclusion Criteria: shellfish allergy intake of anticoagulants and vitamin D pacemaker participating other studies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: vegetable oil with betacarotene<br>4 capsules vegetable oil with betacarotene | |
| Active Comparator: krill and vitamin D3<br>krill and vitamin D3. (72 mg), four capsules daily | Dietary Supplement: Omega Krill with D3<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ADL function on a scale 0-11 |  | february 2013-february 2014 | 
| pain on a scale 0-100 mm |  | february 2013-february 2014 | 
| Quality of life on a scale 0-100 |  | february 2013-february 2014 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| compliance in % |  | february 2013-february 2014 | 
| changes at D3 levels |  | february 2013-february 2014 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pain, quality of life, ADL, DOLO test, compliance, D3
Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements

Study Overview
=================
Brief Summary
-----------------
Plasma Epstein-Barr virus (EBV) DNA will be measured in native plasma samples of nasopharyngeal carcinoma (NPC) patients, respectively, by three medical centers and a qualified laboratory in Southern China, the highest endemic area of NPC. Passing-Bablok regression and difference plots will be used to compare results from each center to the all-method median and mean values. Agreement among methods will be evaluated against bias derived from a biological variation.

Detailed Description
-----------------
The investigators intend to collect EBV DNA positive plasma samples of NPC patients, distribute the samples to four test centers and compare the measurement results to obtain the current status of the agreement of plasma EBV DNA measuring at different centers with various measurement systems in the endemic regions of NPC. A series of statistical analyses including Cohen's Kappa, intraclass correlation coefficient, and Passing-Bablok regression will be adopted for the consistency test. A harmonization study by using the same calibrators will be conducted.

Official Title
-----------------
Verification of Harmonization of Plasma Epstein-Barr Virus DNA Measurements at Multiple Centers in NPC Epidemic Regions

Conditions
-----------------
Nasopharyngeal Carcinoma

Intervention / Treatment
-----------------
* Diagnostic Test: Plasma EBV DNA qPCR test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18-70 years Histologically confirmed NPC or Non-NPC with positive plasma cell-free EBV DNA Exclusion Criteria: unsatisfactory performance status: Karnofsky scale (KPS) <= 70 Any severe intercurrent disease Any contraindication of blood sampling

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| nasopharyngeal carcinoma patients<br>Plasma EBV DNA quantification by quantitative polymerase chain reaction (qPCR) assays in different medical centers. | Diagnostic Test: Plasma EBV DNA qPCR test<br>* Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Plasma EBV DNA | copy number of EBV DNA in plasma | 1 Day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Nasopharyngeal Carcinoma, plasma EBV DNA, Harmonization
Thiol-disulfide Homeostasis in Patients With Ovarian Cancer

Study Overview
=================
Brief Summary
-----------------
Ovarian cancer is the third most common after endometrial and cervical cancer in societies with a high standard of living; It is the second most common type of gynecological cancer after cervical cancer in societies with a low standard of living, and it is also the deadliest among gynecological cancers. Dynamic thiol-disulfide homeostasis is an antioxidant system that minimizes oxidative damage and prevents cell damage. In the presence of oxidative stress, the thiol groups combine to form the disulfide structure, and when the oxidative stress condition is over, they are separated into thiol groups again. This homeostasis is impaired in conditions that cause oxidative processes such as diabetes, cardiovascular diseases, cancers, rheumatoid arthritis, and chronic kidney failure. This can be determined by measuring the total thiol and native thiol levels. Likewise, the level of ischemia modified albumin increases in the case of oxidative stress. There are studies on this homeostasis in the literature on many types of cancer; There are studies on endometrial cancer and cervical cancer, which are gynecological cancers In this study, the usability of these tests together with other diagnostic tests in the diagnosis of ovarian cancer will be evaluated.

Official Title
-----------------
Thiol-disulfide Homeostasis in Patients With Ovarian Cancer

Conditions
-----------------
Ovarian Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histopathological diagnosis of ovarian cancer Exclusion Criteria: Having an acute or chronic disease that will cause oxidative stress Using alcohol/cigarettes/drugs Using antioxidant agents (such as vitamins A, C, E)
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Ovarian cancer<br>The patients with ovarian cancer | |
| Control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| thiol - disulfide levels | the rate of total thiol, native thiol and total oxidant/antioxidant capacity | April 2021 - January 2022 |
Kineret CAPS Post Authorisation Study

Study Overview
=================
Brief Summary
-----------------
A non-interventional, post authorization safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including re-use of syringe.

Official Title
-----------------
Non-interventional PASS to Evaluate Safety of Kineret in Treatment of CAPS in Routine Clinical Care With Regard to Serious Infections, Malignancies, Injection Site Reactions, Allergic Reactions, Medication Errors Including Re-use of Syringe

Conditions
-----------------
Cryopyrin-Associated Periodic Syndromes

Intervention / Treatment
-----------------
* Drug: anakinra (Kineret)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent by the patient and/or caregiver Kineret treatment will be according to the Summary of Product Characteristics (SmPC), as confirmed by the Investigator Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CAPS patients<br>CAPS patients treated with anakinra, using the Kineret graduated syringe | Drug: anakinra (Kineret)<br> <br> * Other names: Kineret;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of serious infections |  | 3 years | 
| Rate of new malignancies |  | 3 years | 
| Rate of injection site reactions |  | 3 years | 
| Rate of allergic reactions |  | 3 years | 
| Rate of medication errors including re-use of syringe |  | 3 years |
Non Invasive Measurement of Cardiac Index by Impedance Cardiography

Study Overview
=================
Brief Summary
-----------------
Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg in the right heart catheterization. There are different forms of PH defined in the classification of Dana Point 2008. PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like echocardiography, stress echocardiography and cardio pulmonary exercise testing. For prognosis of PH patients the limitation of the pulmonary circulation is very important. Therefore the cardiac index (CI) is a good parameter for the right ventricular function. The gold standard for CI measures is the thermodilution, an invasive method performed during right heart catheterization.

Detailed Description
-----------------
In this study the investigators want to evaluate the impedance cardiography (ICG) as a non invasive method for CI measurement. An alternating current of max 400µA and 45 kHz is conducted through the body. The way of the smallest resistance is the blood in the aorta. The impedance changes with the pulsatile blood flow. Out of the Impedance change there can be calculated the CI.

Official Title
-----------------
Non Invasive Measurement of Cardiac Index by Impedance Cardiography

Conditions
-----------------
Pulmonary Hypertension

Intervention / Treatment
-----------------
* Other: Impedance cardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients who have right heart catheterization written informed consent Exclusion Criteria: patients who don't have right heart catheterization no written informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: suspected PH<br>Patients who undergo right heart catheterization for PH diagnosis undergo impedance cardiography | Other: Impedance cardiography<br>* noninvasive measure of cardiac index by impedance cardiography.<br>* Other names: patients with a clinical suspicion of PH;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of CI measured by ICG and Thermodilution | assessment of the Specificity and sensitivity of ICG for CI measurement | recruitment over 1.5 year (Data collection), followed by data analysis and interpretation (overall 2 yearsfrom start of recruitment) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pulmonary hypertension, Cardiac index, impedance cardiography
Evaluation of Patellar Dimension and Bristol Index in Asian Population

Study Overview
=================
Brief Summary
-----------------
Restoration of patellar thickness is pivotal during a total knee arthroplasty (TKA). Several studies showed there are differences in the knee measurements between Asian and Western population. This study aims to evaluate the patellar dimension and Bristol Index of patellar width to thickness (BIPWiT) using magnetic resonance imaging (MRI) in Asian population.

Official Title
-----------------
Evaluation of Patellar Dimension and Bristol Index in Asian Population: an MRI Study

Conditions
-----------------
Patello Femoral Syndrome

Intervention / Treatment
-----------------
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: knee pain Exclusion Criteria: degenerative joint disease patellofemoral pathology

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: MRI|MRI genu non contrast|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bristol index |  | 1 day MRI examination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patellar sizes |  | 1 day MRI examination |
Effect of Artronat on the Quality of Life of Patient With Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the nutritional supplement ARTRONAT improves the quality of life of patients with osteoarthritis.

Detailed Description
-----------------
Osteoarthritis is a degenerative disease that greatly impairs the quality of life of patients. A nutritional supplement may help, in association with the normal treatment of osteoarthritis, improving the quality of life of such patients, in reducing pain and/or improving join flexibility.

Official Title
-----------------
Effet du complément Alimentaire ARTRONAT(R) Sur la réduction de la Gonalgie Chez Des Sujets Arthrosiques

Conditions
-----------------
Osteoarthritis

Intervention / Treatment
-----------------
* Dietary Supplement: ARTRONAT
* Dietary Supplement: PLACEBO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 40-75 years BMI 18.5-30 osteoarthritis type II or III Exclusion Criteria: osteoarthritis type I or IV allergy to one of the component of the supplement blood pressure > 14/8 history of knee surgery

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ARTRONAT<br> | Dietary Supplement: ARTRONAT<br>* Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.<br>|
| Placebo Comparator: PLACEBO<br> | Dietary Supplement: PLACEBO<br>* PLACEBO. 6 per day for 8 months.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of gonalgia | measure with the WOMAC. | T8 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the satisfactory relief of symptoms of osteoarthritis at each visit after the beginning of supplementation, assessed by the patients. | Subjective global assessment measured on a 10-cm graduated scale (Visual Analogue Scale) | T2, T4, T6, T8 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gonalgia, Quality of Life, Dietary supplement, Nutrition
Comparison of Hip Resurfacing to Large Femoral Head Total Hip Arthroplasty

Study Overview
=================
Brief Summary
-----------------
This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.

Official Title
-----------------
Femoral Head Resurfacing Versus a Large Femoral Head (Durom®) Total Hip System: A Prospective Randomized Trial

Conditions
-----------------
Osteoarthritis, Avascular Necrosis

Intervention / Treatment
-----------------
* Procedure: Hip replacement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indication for hip resurfacing because of osteoarthritis or avascular necrosis Aged 19 to 65 years old Ability to give informed consent Exclusion Criteria: Previous fracture requiring internal fixation of the hip Previous hip osteotomy (pelvic or femoral) Dysplasia requiring structural bone graft Inability to respond to questionnaires in English (or French, Montreal centre only) The presence of osteopenia or osteoporosis Evidence of hepatic/renal insufficiency or failure from medical history or laboratory assessment

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To estimate the difference in postoperative quality of life between patients with Durom® hip resurfacing versus those with total hip arthroplasty (THA) using a large-head, metal-on-metal articulation |  | at 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To estimate the difference in concentrations of cobalt and chromium ions in serum |  |  | 
| To estimate the difference in gait (pelvic tilt, forward velocity, and cadence) |  | at 12 and 52 weeks | 
| To estimate the lower limb functional instability by a test of postural balance |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hip, Osteoarthritis/Avascular Necrosis